drugset / Trial / NCT07110103
Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC
Phase 2
Recruiting
20 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Dizal (Jiangsu) Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single-arm, phase 2 study to evaluate the safety and efficacy of golidocitinib with PD-1 inhibitors as maintenance treatment in patients with previously untreated extensive-stage small cell lung cancer.
Timeline
- Start
- 2025-10-31
- Primary completion
- 2027-03-31
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Golidocitinib | Small molecule | 75 mg | — |
| Subject | Golidocitinib | Small molecule | 150 mg | — |